Free tools Windows power users keep installed
One-click scans. No signup required.
Yes. On November 21, 2023, four Democratic members of the U.S. House asked the Securities and Exchange Commission (SEC) to investigate whether Elon Musk made intentionally misleading statements to investors about Neuralink’s animal-testing safety. Their request raised a potential securities-fraud issue; it was not an SEC finding that Musk or Neuralink violated the law.
What did the lawmakers ask the SEC to investigate?
Representatives Earl Blumenauer of Oregon, Jim McGovern of Massachusetts, Barbara Lee of California, and Tony Cardenas of California asked the SEC to examine Musk’s public statements about monkeys used in Neuralink experiments. Reuters reported the request on November 22, 2023, after the lawmakers sent their letter on November 21. The letter asked whether Musk, Neuralink’s CEO, had made intentionally misleading statements to investors about safety. Reuters, republished by Investing.com.
| # | Preview | Product | Price | |
|---|---|---|---|---|
| 1 |
|
Million Muskmelons: How To Be Like Elon Musk: Unveiling the Secrets of Elon Musk's Success | $1.03 | Buy on Amazon |
The request was an allegation seeking regulatory scrutiny—not a charge, court ruling, or determination by the SEC. The letter’s language, reproduced by Tech Times, asked the agency to investigate whether Musk “committed securities fraud by making intentionally misleading statements to investors.” That wording describes what the lawmakers wanted the SEC to examine, not a conclusion reached by the agency. Tech Times.
What safety statements prompted the request?
The dispute centered on a September 10, 2023 post by Musk on X: “No monkey has died as a result of a Neuralink implant.” He also said Neuralink selected “terminal” monkeys—animals he described as close to death already—to minimize risks to healthy monkeys. These statements were the subject of the lawmakers’ challenge; their interpretation was not an SEC finding. Reuters and the Physicians Committee for Responsible Medicine (PCRM) reported the statements and dispute. Reuters; PCRM.
Do these 3 things before closing this tab:
1Scan for outdated or missing drivers - takes under a minute2Clear out junk files and repair common Windows errors3Fix the driver behind crashes, sound loss and screen glitches#1 Best Overall
What records and animal outcomes did critics cite?
Reuters reported that the lawmakers’ letter cited veterinary records from Neuralink’s monkey experiments and described serious health effects, including paralysis, seizures, and brain swelling. According to Reuters’ account of the letter, it said at least 12 young, healthy monkeys were euthanized “as a direct result of problems with the company’s implant.” Those figures and claims are the lawmakers’ account as reported by Reuters, not an independently adjudicated regulatory finding.
PCRM, an advocacy organization that filed its own request for an SEC investigation, said records it obtained through a lawsuit against the University of California, Davis showed that 12 previously healthy animals were euthanized by Neuralink as a direct result of implant problems. PCRM reported the animals’ average age as 7.25 years and described chronic infections, paralysis, brain swelling, loss of coordination and balance, and depression. These are PCRM’s descriptions of records it obtained; PCRM is not a regulator or court. PCRM.
The competing language matters: Musk’s post referred to whether a monkey died “as a result of” an implant, while critics cited records they said linked euthanasia and severe conditions to implant problems. The public accounts summarized here establish that the statements and records were disputed; they do not provide an SEC or court resolution of that dispute.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.Was there an SEC investigation, and what is its status?
In December 2024, the Associated Press reported that a letter from Musk’s lawyer alleged the SEC had reopened a Neuralink investigation. The SEC did not release the letter, confirm the alleged reopening, or comment on the matter; an agency spokesperson said investigations are conducted confidentially. Associated Press.
An April 2025 Senate minority-staff memorandum discussed Exchange Act Section 10(b) and Securities Act Sections 17(a)(2) and 17(a)(3) as provisions that could be implicated if a Neuralink investigation remained active. The memo’s discussion was conditional and said it was unclear whether an investigation remained active; it was not an SEC decision or judicial ruling. U.S. Senate minority-staff memorandum.
The SEC’s litigation-releases listing, checked October 8, 2026, does not identify an outcome for the Neuralink allegations. A public litigation listing cannot establish whether a confidential investigation occurred, remains open, or was closed without public action. SEC litigation releases. The public sources cited here therefore do not establish a final SEC finding, charge, or closure in this matter.
What investors should take from the allegations
The episode illustrates why a request for an investigation should be distinguished from an enforcement result. The lawmakers alleged that Musk’s statements could have misled investors; PCRM offered its own account of animal records; Musk’s lawyer later alleged that the SEC had reopened an investigation; and the SEC did not confirm that allegation. None of those steps, on its own, proves securities fraud. The cited materials do not establish that the SEC concluded Musk’s statements were false or that investors suffered legally actionable harm.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
